Cargando…

Predicting disease progression and poor outcomes in patients with moderately active rheumatoid arthritis: a systematic review

OBJECTIVES: Access to biologic DMARDs for RA is often restricted to those with severe disease. This systematic review aimed to identify prognostic factors in patients with moderate disease activity who may be at risk of disease progression and poor clinical outcomes. METHODS: MEDLINE, Embase and Coc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Edwards, Christopher J, Kiely, Patrick, Arthanari, Subhashini, Kiri, Sandeep, Mount, Julie, Barry, Jane, Mitchell, Catherine R, Field, Polly, Conaghan, Philip G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6649936/ https://www.ncbi.nlm.nih.gov/pubmed/31431990 http://dx.doi.org/10.1093/rap/rkz002

Ejemplares similares

Factors associated with disability in patients with rheumatoid arthritis with persistent moderate disease activity: a retrospective cohort study
por: Scott, Ian C., et al.
Publicado: (2020)

Evaluating the efficacy of upadacitinib in patients with moderate rheumatoid arthritis: a post-hoc analysis of the SELECT phase 3 trials
por: Conaghan, Philip G, et al.
Publicado: (2023)

Comparative clinical utility of once-weekly subcutaneous abatacept in the management of rheumatoid arthritis
por: Rakieh, Chadi, et al.
Publicado: (2014)

Large joints are progressively involved in rheumatoid arthritis irrespective of rheumatoid factor status—results from the early rheumatoid arthritis study
por: Zhao, Sizheng Steven, et al.
Publicado: (2021)

Benefit–Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis
por: Conaghan, Philip, et al.
Publicado: (2021)

Baseline Objective Inflammation by Magnetic Resonance Imaging as a Predictor of Therapeutic Benefit in Early Rheumatoid Arthritis With Poor Prognosis
por: Ahmad, Harris A., et al.
Publicado: (2020)

The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: results from the ACT-RAY MRI substudy
por: Conaghan, Philip G, et al.
Publicado: (2014)

A longitudinal evaluation of the Center for Epidemiologic Studies-Depression scale (CES-D) in a Rheumatoid Arthritis Population using Rasch Analysis
por: Covic, Tanya, et al.
Publicado: (2007)

Variability in depression prevalence in early rheumatoid arthritis: a comparison of the CES-D and HAD-D Scales
por: Covic, Tanya, et al.
Publicado: (2009)

RNA Editing–Associated Post-Transcriptional Gene Regulation in Rheumatoid Arthritis
por: Ghanekar, Yashoda, et al.
Publicado: (2022)

Changes in the pharmacological management of rheumatoid arthritis over two decades
por: Crossfield, Samantha S R, et al.
Publicado: (2021)

Fatigue in early rheumatoid arthritis: data from the Early Rheumatoid Arthritis Network
por: Ifesemen, Onosi Sylvia, et al.
Publicado: (2021)

Disease impact of rheumatoid arthritis in patients not treated with advanced therapies; survey findings from the National Rheumatoid Arthritis Society
por: Nikiphorou, Elena, et al.
Publicado: (2021)

Modulation of peripheral T-cell function by interleukin-7 in rheumatoid arthritis
por: Churchman, Sarah M, et al.
Publicado: (2014)

Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis
por: Peterfy, Charles, et al.
Publicado: (2016)

Imaging in rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and osteoarthritis: An international viewpoint on the current knowledge and future research priorities
por: Baraliakos, Xenofon, et al.
Publicado: (2019)

Very early MRI responses to therapy as a predictor of later radiographic progression in early rheumatoid arthritis
por: Conaghan, Philip G., et al.
Publicado: (2019)

T-bet expression in rheumatoid arthritis patients with early, disease-modifying anti-rheumatic drug naïve disease is low and correlates with low levels of IL-7 and T-cell dysfunctions
por: Ponchel, F, et al.
Publicado: (2005)

Secular changes in the progression of clinical markers and patient-reported outcomes in early rheumatoid arthritis
por: Carpenter, Lewis, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK
por: Schweikert, Bernd, et al.
Publicado: (2020)

Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis
por: Hushaw, Linda L, et al.
Publicado: (2010)

Patient involvement in the development of a handbook for moderate rheumatoid arthritis
por: Prothero, Louise, et al.
Publicado: (2016)

The role of upadacitinib in the treatment of moderate-to-severe active rheumatoid arthritis
por: Avci, Ali Berkant, et al.
Publicado: (2021)

Depression and anxiety in patients with rheumatoid arthritis: prevalence rates based on a comparison of the Depression, Anxiety and Stress Scale (DASS) and the hospital, Anxiety and Depression Scale (HADS)
por: Covic, Tanya, et al.
Publicado: (2012)

Biologic agents for rheumatoid arthritis—negotiating the NICE technology appraisals
por: Kiely, Patrick D. W., et al.
Publicado: (2012)

A Matching-Adjusted Indirect Comparison of Upadacitinib Versus Tofacitinib in Adults with Moderate-to-Severe Rheumatoid Arthritis
por: Edwards, Christopher J., et al.
Publicado: (2020)

Direct healthcare resource utilisation, health-related quality of life, and work productivity in patients with moderate rheumatoid arthritis: an observational study
por: Galloway, James, et al.
Publicado: (2021)

Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future
por: Schett, Georg, et al.
Publicado: (2011)

Discordant inflammation and pain in early and established rheumatoid arthritis: Latent Class Analysis of Early Rheumatoid Arthritis Network and British Society for Rheumatology Biologics Register data
por: McWilliams, Daniel F., et al.
Publicado: (2016)

Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study
por: Emery, Paul, et al.
Publicado: (2020)

Targeted literature review of current treatments and unmet need in moderate rheumatoid arthritis in the United Kingdom
por: Taylor, Peter C, et al.
Publicado: (2021)

Tender and swollen joint counts are poorly associated with disability in chikungunya arthritis compared to rheumatoid arthritis
por: Watson, Hugh, et al.
Publicado: (2021)

Determining MRI Inflammation Targets When Considering a Rheumatoid Arthritis Treat-to-Target Strategy: Results of a Randomized, Placebo-Controlled Trial
por: Ahmad, Harris A., et al.
Publicado: (2019)

The Differential Effect of Antibodies on Radiographic Progression in Rheumatoid Arthritis
por: Minocha, Amal, et al.
Publicado: (2020)

Exploratory analyses of the association of MRI with clinical, laboratory and radiographic findings in patients with rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2011)

Benefits of Autoantibody Enrichment in Early Rheumatoid Arthritis: Analysis of Efficacy Outcomes in Four Pooled Abatacept Trials
por: Michaud, Kaleb, et al.
Publicado: (2023)

Circulating levels of IL-7 in rheumatoid arthritis
por: Churchman, S, et al.
Publicado: (2007)

Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity
por: Hyrich, Kimme L., et al.
Publicado: (2009)

Certolizumab pegol in a heterogeneous population of patients with moderate-to-severe rheumatoid arthritis
por: Soriano, Enrique R, et al.
Publicado: (2018)

Associations between fatigue and physical capacity in people moderately affected by rheumatoid arthritis
por: Demmelmaier, Ingrid, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_havac1lrh03erm2d6fjaa55o5b